Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
Sanofi-Aventis S.A. ADR
(NQ:
SNY
)
57.63
-0.63 (-1.08%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Sanofi-Aventis S.A. ADR
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
30
31
Next >
7 Blue-Chip Stocks to Buy for Quality-Focused Investors
March 06, 2023
With circumstances shaky in the market right now, concerned investors may want to consider blue-chip stocks to buy.
Via
InvestorPlace
Sanofi Could Be on a Roll With a Strong Performance and Its Latest FDA Approval
March 06, 2023
The French drug company got the nod for a hemophilia treatment.
Via
The Motley Fool
FDA Approves Regeneron-Sanofi's Sarilumab As First Biologic For Stiffness, Pain In Muscles
March 01, 2023
Via
Benzinga
Eli Lilly Slashes Insulin Prices By 70%, Will Other Insulin Makers Follow Suit?
March 01, 2023
Eli Lilly & Co (NYSE: LLY), in an effort to make it easier for patients to access affordable insulin and navigate the complex healthcare system, announced on Wednesday a 70% reduction in the list price...
Via
Benzinga
The Next Generation Of Cancer Vaccines Are Coming; What That Means For Moderna And Other Biotech Stocks
February 24, 2023
Startling cancer vaccine results from Moderna may point to the next big thing in biotech.
Via
Investor's Business Daily
FDA Approves Sanofi's Hemophilia A Therapy Offering Significant Bleed Protection
February 24, 2023
Via
Benzinga
Sanofi (SNY) Q4 2022 Earnings Call Transcript
February 03, 2023
SNY earnings call for the period ending December 31, 2022.
Via
The Motley Fool
Earnings Outlook For Sanofi
February 02, 2023
Via
Benzinga
Analyst Confidence in Eli Lilly Boosted by Product Pipeline
February 22, 2023
Eli Lilly has long been a reliable stock, but with the company's impressive product pipeline, the stock could hold significant potential in the near term.
Via
MarketBeat
Moderna Hypes 'Important Step' In Flu Shot Results, But Market Disagrees
February 17, 2023
Shares crumbled after Moderna's flu shot outperformed in just one flu strain.
Via
Investor's Business Daily
Market Rally Powers Higher On Tame Fed, Meta Earnings; Apple, Google, Amazon In Focus: Weekly Review
February 03, 2023
The major indexes continued to run despite mixed-to-weak earnings.
Via
Investor's Business Daily
Hopeful Golden Cross Forms On Sanofi's Chart
January 26, 2023
Via
Benzinga
BioRestorative (NASDAQ: BRTX) Ramps Up Production In Anticipation Of Positive Phase 2 Results
February 03, 2023
Chronic lumbar disc disease (cLDD) is a debilitating condition affecting millions of people worldwide. It is characterized by back pain, stiffness, and restricted movement due to damage to the bony...
Via
Benzinga
Regeneron Pharma Outplays Fourth-Quarter Decline, But Sanofi Stock Topples
February 03, 2023
Regeneron beat forecasts despite wide declines. But Sanofi fell on its mixed report.
Via
Investor's Business Daily
Nasdaq Futures Deflate As Apple Leads Tech Disappointments: Traders Look To Jobs Data For Mitigating Impact
February 03, 2023
Trading in the U.S. index futures suggests stocks may end a solidly positive week on a negative note. That said, the data-dependency of the Fed places the onus of providing trading cues to each...
Via
Benzinga
Sanofi Expects Moderate 2023 Profit Growth On Dupixent Demand, But Dampened By Aubagio Generics Competition
February 03, 2023
Via
Benzinga
Alphabet, Apple And 3 Stocks To Watch Heading Into Friday
February 03, 2023
With Nasdaq stock futures trading lower this morning on Friday, some of the stocks that may grab investor focus today are as follows:
Via
Benzinga
Fear & Greed Index Remains In 'Greed' Zone As Nasdaq Record Sharp Gains For Fourth Straight Week
February 03, 2023
The CNN Money Fear and Greed index showed some decline in overall sentiment among US investors. US stocks closed mostly higher on Thursday, with the tech-laden Nasdaq index leading the rally. Investors...
Via
Benzinga
February PDUFA Catalysts Biotech Investors Must Know: Sanofi's Bleeding Disorder Drug, Regeneron's Twin Eylea Label Expansions, 3 Delayed Approvals And More
January 31, 2023
The year has started well for biopharma companies on the regulatory front, as most decisions handed out during January were positive. The Food and Drug Administration has already cleared four new...
Via
Benzinga
Sanofi Layoffs 2023: What to Know About the Latest SNY Job Cuts
January 31, 2023
One French pharmaceutical producer is implementing job cuts. Here's what investors need to know about the Sanofi layoffs.
Via
InvestorPlace
Sanofi Might Pull Down Shutters For Two Vaccine Plants In India
January 30, 2023
After Sanofi SA (NASDAQ: SNY) failed to secure a UNICEF contract, the company is weighing closing operations at two of its vaccine-making facilities in Hyderabad, India, and plans to let go of all...
Via
Benzinga
Europe Approves Regeneron-Sanofi's Dupixent For Expanded Use In Eosinophilic Esophagitis
January 30, 2023
Via
Benzinga
Dupixent® (dupilumab) Approved by European Commission as the First and Only Targeted Medicine Indicated for Eosinophilic Esophagitis
January 30, 2023
From
Regeneron Pharmaceuticals, Inc.
Via
GlobeNewswire
Could This Vaccine Become Sanofi's Latest Blockbuster?
January 29, 2023
This vaccine candidate could be approved in newborns and infants later this year.
Via
The Motley Fool
7 Blue-Chip Stocks to Buy as a New Bull Market Emerges
January 26, 2023
Many blue-chip stocks look like a bargain right now, and these seven companies are certainly no exception.
Via
InvestorPlace
Can Market Sustain Upward Momentum In Tech-Heavy Earnings Week? Apple, Amazon, AMD, Alphabet, Ford Among Key Quarterly Reports To Watch
January 29, 2023
With a full week of earnings behind us, it’s time to take stock of the fourth-quarter reporting season so far. Overall, the news flow has been mixed, although tech earnings have grossly disappointed.
Via
Benzinga
Mergers and Acquisitions in 2023 Off To A Strong Start
January 26, 2023
Mergers and acquisitions are common, especially across the health sector. Here are some lesser-known buyouts and how they could fare down the road.
Via
MarketBeat
Exposures
Product Safety
Wall Street Thinks These 2 Blazing Healthcare Stocks Could Have 21% to 30% Upside in 2023
January 23, 2023
It's difficult to imagine a future where healthcare isn't in high demand.
Via
The Motley Fool
Pharmaceutical Stocks Pfizer, GSK, Moderna Come Close To Cracking A Multibillion-Dollar RSV Vaccine Market
January 19, 2023
After years of lab failures, the companies could crack open a multibillion-dollar market.
Via
Investor's Business Daily
The Viral “Tripledemic” Opportunity
January 14, 2023
Between Covid, the flu, and RSV, investors in over-the-counter consumer pharmaceutical companies might be wondering if now is a logical time to up their holdings in the companies that make cold and flu...
Via
Talk Markets
< Previous
1
2
...
11
12
13
14
15
16
17
18
19
...
30
31
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.